An EBF team consisting of: Philip Timmerman, Morten Anders Kall, Ben Gordon, Sirpa Laakso, Achim Freisleben and Richard Huckerhas published EBF's views on the impact of the MIST guidance on the bioanalytical laboratory.
Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum
The relationship between the exposure to drug metabolites and overall drug safety has become an integral part of the drug-development process. In-depth discussions in the scientific community, as well as recent guidelines on Drug Safety Testing of Metabolites from the US FDA (often referred to as the MIST guidance and ICH M3(R2) from the International Conference on Harmonization (ICH), has brought clarity to the regulatory requirements of the sponsor company in providing documentation on circulating levels of qualifying metabolites. However ....
Read more
Download full paper
Monday, August 2, 2010
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment